Refractory diabetic macular edema (DME) to monthly intravitreal anti-vascular endothelial
growth factor (VEGF) monotherapy has a prevalence of approximately 40% in landmark …

Diabetic macular edema (DME), characterized by exudative fluid accumulation in the
macula, is the most common form of sight-threatening retinopathy in patients with diabetes …

Background To evaluate functional and anatomical consequences of switching anti-vascular
endothelial growth factor (anti-VEGF) therapy from bevacizumab and/or ranibizumab to …

Given the rising prevalence of patients with diabetes and increasing treatment burden for
patients with vision-threatening diabetic macular edema (DME), we aimed to explore the …

Objective To assess the functional and anatomical effects of transitioning to conbercept
intravitreal injection (IVC) treatment in patients with diabetic macular edema (DME) who had …

Introduction Diabetic macular edema (DME) is a common cause of vision loss in patients
with diabetic retinopathy and occurs in a substantial proportion of patients with long …

Background: Recent evidence on the role of vascular endothelial growth factor (VEGF) in the
pathogenesis of ischemia and microvascular hyperpermeability leading to macular edema …

The aim of the present study was to investigate changes in metamorphopsia in patients with
diabetic macular edema (DME) following intravitreal aflibercept injection (IVA) with the treat …

Retinal neovascularization (RNV) is a common pathology of blinding proliferative
retinopathies. The current treatments to RNV, however, are hindered by limited efficacy, side …